Live
- Govt plans to establish offshore Johns Hopkins University Campus in India
- Goa Aces clinch Indian Racing League title
- Study finds how hormone therapy can reshape the skeleton
- High-street fashion players looking at India for manufacturing: Report
- Shreyas Iyer to lead Mumbai as Prithvi Shaw returns for Syed Mushtaq Ali Trophy
- 'Failed to resolve crisis': NPP withdraws support from BJP govt in Manipur
- Chennai: Actress Kasturi Remanded in Custody Until 29th of This Month
- Aaqib Javed likely to become Pakistan's new white-ball head coach
- BJP panel to draft poll charge sheet against AAP govt in Delhi
- Allu Arjun Thanks Fans in Patna, Teases 'Pushpa 2' Release
Aurobindo gets FDA nod for new drug
City-based Aurobindo Pharma has received final approval from USFDA to manufacture and market Ibandronate Sodium tablets, used for the treatment and prevention of osteoporosis in women, in the American market.
Hyderabad: City-based Aurobindo Pharma has received final approval from USFDA to manufacture and market Ibandronate Sodium tablets, used for the treatment and prevention of osteoporosis in women, in the American market.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Ibandronate Sodium Tablets, 150 mg," Aurobindo Pharma Limited said. The new drug is expected to be launched in the first quarter of next fiscal.
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product Boniva Tablets of Hoffman-La Roche Inc, it added. The approved product has an estimated market size of $ 55 million for the twelve months ending January 2016 according to IMS.
Ibandronate Sodium Tablets is used in the treatment and prevention of osteoporosis in postmenopausal women. Aurobindo currently has a total of 243 ANDA approvals (208 final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from the US.
